Mark Lampert‘s Biotechnology Value Fund reported raising its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to 3.11 million shares, which account for 17.9% of the company’s outstanding stock, via a newly-amended 13G filing released by the Securities and Exchange Commission. Previously, the fund held 1.78 million shares or 12.3% of Xenon’s outstanding stock, according to its 13F filing for the June 30 reporting period.
As the name denotes it, Xenon Pharmaceuticals is a clinical stage biopharmaceutical company that develops various therapeutics for orphan indications. Recently, the company made a $30 million public offering of common shares, priced at $7.50 per share. Year-to-date, Xenon Pharmaceuticals’ stock is down by 4.48%. In its latest financial report, for the second quarter of 2016, the company disclosed revenue of $0.4 million and a basic loss per share of $0.42, compared to a revenue of $4.04 million and earnings per share of $0.08, for the corresponding period of the prior year.
wavebreakmedia/Shutterstock.com
Among the hedge funds from Insider Monkey’s database, seven were long Xenon Pharmaceuticals (NASDAQ:XENE) at the end of June, down from eight a quarter earlier. Some of the bullish investors contained Steve Cohen’s Point72 Asset Management, with a position valued at $2.12 million, and Jim Simons’ Renaissance Technologies, which held a position worth around $286,000.
Follow Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Follow Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Biotechnology Value Trading Fund OS | 0 | 262,664 | 0 | 262,664 | 262,664 | 1.5% |
| BVF Partners OS Ltd | 0 | 262,664 | 0 | 262,664 | 262,664 | 1.5% |
| BVF Partners | 0 | 3,108,905 | 0 | 3,108,905 | 3,108,905 | 17.9% |
| BVF Inc | 0 | 3,108,905 | 0 | 3,108,905 | 3,108,905 | 17.9% |
| Mark N. Lampert | 0 | 3,108,905 | 0 | 3,108,905 | 3,108,905 | 17.9% |
Follow Mark Lampert's Biotechnology Value Fund / BVF Inc
Page 1 of 10 – SEC Filing
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
| Xenon Pharmaceuticals Inc. |
| (Name of Issuer) |
| Common Shares, no par value per share |
| (Title of Class of Securities) |
| 98420N 10 5 |
| (CUSIP Number) |
| September 8, 2016 |
| (Date of Event Which Requires Filing of this Statement) |
| o | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
_______________
